NEW YORK, NY / April 08, 2020 / CLS Therapeutics, a privately held anticancer gene therapy platform company addressing a novel therapeutic target, announces presentation at the upcoming 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting that will be held from April 29 to May 2, 2019 that is planned to be held May 12 – May 15, 2020, at the Hynes Convention Center in Boston, USA.
A poster presentation named “First-In-Class AAV-Based Gene Therapy for Pancreatic Cancer and Other Tumors Based on the Destruction of Cell-Free DNA with Vector-Delivered DNase I” will showcase CLS’ data for the use of their CLS-014 drug candidate. CLS has identified a new therapeutic target (blood tumor- and neutrophils- derived cell-free DNA) for the successful anticancer therapy for multiple cancers and their initial indication is pancreatic cancer. Thus, CLS revolutionizes cancer therapy, since the proposed target was shown to play a primary role in the failure of existing anticancer therapies (and has been independently confirmed by leading universities and research groups). The Company uses smart AAV technology for the delivery of gene to the liver, after which, hepatocytes in a 48 hours start to produce recombinant human enzyme that destroys this cell-free DNA.
The data that will be presented is exemplifies how CLS’ cutting-edge gene therapy capabilities can be leveraged to potentiate first-line chemotherapy, decrease primary tumor growth and prevent metastases formation in pancreatic cancer models. Furthermore, Dr. Tetz, MD, PhD., Chief Executive Officer of CLS Therapeutics, will be participating in the Scientific Symposiums.
Poster presentation details:
First-In-Class AAV-Based Gene Therapy for Pancreatic Cancer and Other Tumors Based on the Destruction of Cell-Free DNA with Vector-Delivered DNase I
George Tetz1, MD, PhD, Casey A Maguire3, PhD, Allan Tsung MD, Dmitry Genkin1 MD, Victor Tetz2 MD, PhD
1CLS Therapeutics Institute, New York, NY, 10013 USA
2Human Microbiological Institute, New York, NY, 10013 USA
3Molecular Neurogenetics Unit, Massachusetts General Hospital, Harvard Medical
4Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
Thursday May 14, 2020 5:30 PM – 6:30 PM
Session Title: Cancer – Targeted Gene and Cell Therapy
Room: Exhibit Hall C & D
Final abstract number: 1178
Abstracts will be also available on the ASGCT website. The poster presentations to be presented at the 2020 ASGCT Annual Meeting will be available on the CLS Therapeutics website after May 14, 2020.
Jenene Thomas Communications LLC
CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Targeting Tumor Heterogeneity Conference organized by the New York Academy of Sciences May 8, 2019, in New York, New York.
CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “CELL-FREE TUMOR DNA AND NEUTROPHIL EXTRACELLULAR TRAPS AS NOVEL THERAPEUTIC TARGETS FOR PANCREATIC CANCER” at the Frontiers in Cancer Immunotherapy organized by the New York Academy of Sciences May 14-15, 2019, in New York, New York.
NEW YORK, NY / May 14, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data on its AAV therapy clinical candidate, CLS-014, this week at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT).